We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Filtration Method Developed for Cord Blood

By LabMedica International staff writers
Posted on 27 Dec 2012
Print article
A novel filtration system using a nonchemical-coated and nonwoven polyester fabric filter, which traps cells through affinity, has been developed for cord blood.

Cord blood (CB) is being increasingly used as a source of hematopoietic stem cells for transplantation to treat diseases of the blood and immune systems, and there is an urgent need to expand CB banking worldwide.

Scientists at Kyushu University School of Medical Science (Fukuoka, Japan) developed a polyester fabric filter specifically for CB, which traps cells and does not require centrifugation or potentially toxic chemicals. Normally CB processing requires costly machinery or a clean room that hampers wider application of cord blood transplantation (CBT) particularly in the developing countries.

The collection efficacy was calculated by counting total nucleated cells (TNCs) using an automated hematology analyzer KX-21 (Sysmex; Kobe, Japan) or ABX Pentra hematology analyzer (Horiba; Kyoto, Japan). The red blood cell (RBC) compartment combines the RBCs and the nucleated red cells. The number of mononuclear cells (MNCs) or polymorphonuclear cells (PMNs) was calculated as the product of TNC count, and the percentage of each population analyzed by FACSCanto flow cytometry (BD Biosciences; San Jose, CA, USA). Collection efficacy was defined as the ratio of cell number in the collected fraction relative to the introduced cord blood.

The loss of TNCs, MNCs, and PMNs was less than 5%. The loss of CD34+ cells was only 0.5%, indicating the minimal loss of nucleated cells and CD34+ cells during this process. On the other hand, 84.8% of RBCs and 61.0% of platelets were in the flow-through fraction. These data indicated that the device could trap nucleated cells and remove RBCs and platelets efficiently. Therefore cell processing with the device resulted in minimum cell loss of total cells and CD34+ cells, without impairing the ability of CD34+ cells to engraft and differentiate both in vivo and in vitro.

The authors concluded that CB processing with the device is simple, cost-effective, and nontoxic without requiring costly equipment will facilitate international CB banking. This will help in meeting the increasing worldwide demand for CB for allogeneic hematopoietic stem cell transplantation. The study was published on December 14, 2012, in the International Journal of Laboratory Hematology.

Related Links:
Kyushu University School of Medical Science
Sysmex
Horiba


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.